By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


BiPar Sciences, Inc. 

1000 Marina Boulevard
Suite 550
Brisbane  California  94005  U.S.A.
Phone: 650-635-6050 Fax: 650-635-6057


Start Up

Company News
Positive Phase II Results with Sanofi-Aventis (France) (SASY.PA) and BiPar Sciences, Inc.'s Iniparib (BSI-201) in Women with Metastatic Triple Negative Breast Cancer Published in The New England Journal of Medicine 1/6/2011 7:42:36 AM
New Executive Leadership and CEO Announced for BiPar Sciences, Inc. 12/11/2009 7:56:59 AM
BiPar Sciences, Inc. Co-founder Reunites Management Team At TriAct Therapeutics to Advance Clinical Stage Cancer Programs 9/10/2009 8:59:39 AM
US Oncology, Inc. (USON): US Oncology Research Network Participates in Phase III Follow-up Study To US Oncology, Inc. (USON)'s Investigational Cancer Drug BSI-201 7/23/2009 2:03:50 PM
US Oncology, Inc. (USON) Research Network Participates in Phase III Follow-up Study to BiPar's Investigational Cancer Drug BSI-201 Phase II of the Trial was Presented in 2009 BiPar Sciences, Inc. Plenary Session 7/20/2009 9:02:50 AM
Sanofi-Aventis (France) (SASY.PA) and BiPar Sciences, Inc. Release: BSI-201 Enters Phase 3 in Metastatic Triple Negative Breast Cancer 7/17/2009 8:44:45 AM
New BiPar Sciences, Inc. Drug Class Promising in Breast Cancer 6/1/2009 7:13:50 AM
BiPar Sciences, Inc.' Investigational PARP Inhibitor, BSI-201, to be Highlighted During American Society of Clinical Oncology's Plenary Session 5/18/2009 11:56:41 AM
Sanofi-Aventis (France) (SASY.PA) Buys U.S. Cancer Firm, BiPar Sciences, Inc. for up to $500 Million 4/15/2009 7:09:49 AM
BiPar Sciences, Inc. to Present At the 11th Annual BIO CEO & Investor Conference in New York City 2/3/2009 8:22:34 AM